PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

micafungin Side Effects

The reactions most often reported to the FDA for micafungin (also sold as Mycamine), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

4,779
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of micafungin come from 4,779 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 4,779 reports to the FDA Adverse Event Reporting System (FAERS) for micafungin (Mycamine): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

4,779

Reports Mentioning Death

1,712

35.8% of reports — not proof the medicine caused the death

Hospitalizations

2,379

49.8% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PYREXIA
281
FEBRILE NEUTROPENIA
258
MULTIPLE ORGAN DYSFUNCTION SYNDROME
213
ACUTE KIDNEY INJURY
204
RESPIRATORY FAILURE
193
PNEUMONIA
190
SEPSIS
188
NEUTROPENIA
176
SEPTIC SHOCK
168
DIARRHOEA
167
CONDITION AGGRAVATED
163
CANDIDA INFECTION
142
ASPERGILLUS INFECTION
127
BRONCHOPULMONARY ASPERGILLOSIS
127
DEATH
127
HYPOTENSION
125
DRUG INTERACTION
123

Who Reports Side Effects

Gender Distribution

Female 1,706 (39%)
Male 2,648 (61%)
Unknown 16

Age Distribution

0-17 804 (20%)
18-44 975 (24%)
45-64 1,260 (31%)
65-74 731 (18%)
75+ 340 (8%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,712 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME 197
RESPIRATORY FAILURE 133
SEPTIC SHOCK 131
DEATH 126
SEPSIS 116
PNEUMONIA 109
CANDIDA INFECTION 89
CONDITION AGGRAVATED 87
PYREXIA 80
NEUTROPENIA 76
ACUTE KIDNEY INJURY 75
RENAL FAILURE 70
FEBRILE NEUTROPENIA 63
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 57
ASPERGILLUS INFECTION 56
DIARRHOEA 54
HYPOTENSION 53

Reactions in Hospitalization Reports

Top reactions in 2,379 reports where hospitalization was an outcome.

Reaction Reports
PYREXIA 186
FEBRILE NEUTROPENIA 185
RESPIRATORY FAILURE 134
ACUTE KIDNEY INJURY 133
MULTIPLE ORGAN DYSFUNCTION SYNDROME 127
PNEUMONIA 123
SEPSIS 118
SEPTIC SHOCK 103
HYPOTENSION 96
CONDITION AGGRAVATED 95
DIARRHOEA 91
NEUTROPENIA 89
BRONCHOPULMONARY ASPERGILLOSIS 86
CANDIDA INFECTION 83
PANCYTOPENIA 74
ASPERGILLUS INFECTION 73
INFECTION 66

Compare micafungin vs acyclovir →

What the FAERS Data Reveals About micafungin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 4,779 voluntary reports linked to micafungin and its brand equivalents (Mycamine), spanning 2004 through 2025. Of those, 1,712 (35.8%) listed death as an outcome and 2,379 (49.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 39% were female and 61% male; age distribution skews toward 45-64, with 1,260 reports in that bracket. The single most reported reaction is pyrexia with 281 submissions, followed by febrile neutropenia and multiple organ dysfunction syndrome.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.